AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca is conducting an open-label Phase 3 study titled ‘An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia’. The study aims to evaluate the safety, efficacy, and tolerability of sodium zirconium cyclosilicate (SZC) in children under 18 years old with hyperkalaemia. Approximately 140 participants will be enrolled across 46 sites in Europe and North America.
The intervention being tested is sodium zirconium cyclosilicate (SZC), a drug that has been effective in treating hyperkalaemia in adults. The study will assess its use in children, with doses adjusted based on body weight to mirror adult treatment regimens.
This study employs a single-group, open-label design with no masking. Participants will undergo three phases: a Correction Phase (CP), a Maintenance Phase (MP), and a Long-term Maintenance Phase (LTMP), with the primary aim of achieving and maintaining normokalaemia.
The study began on April 2, 2019, with an estimated completion date of December 27, 2024. The latest update was submitted on July 17, 2025, indicating ongoing recruitment and data collection.
The successful development of SZC for pediatric use could positively impact AstraZeneca’s stock performance by expanding its market reach. This study positions AstraZeneca ahead of competitors in pediatric hyperkalaemia treatment, potentially boosting investor confidence.
The study is currently ongoing, with further details available on the ClinicalTrials portal.